

Form PTO-1595 (Rev. 06/04)

U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark OfficeRECORDATION FORM COVER SHEET
PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office. Please record the attached documents or the address(es) below..

1. Name of conveying party(ies)/Execution Date(s):

ALPHARMA AS

Execution/Effective Date(s): 10/19/2005

Additional name(s) of conveying party(ies) attached?

attached? ☐ Yes ☒ No

2. Name and address of receiving party(ies):

NAME: LYTIX Biopharma

ADDRESS: Universitetet i Tromsø
Forskningsavdelingen
9037 Tromsø
Norway

3. Name of Conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Government Interest Assignment
☐ Executive Order 9424, Confirmatory License
☐ Other

Additional name(s) & addresses(es) attached?

☐ Yes ☒ No4. Application number(s) or patent number(s): ☐

This document is being filed together with a new application

A. Patent Application No.(s)

10/221,040

B. Patent No.(s)

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Barbara G. Ernst
 Address: Rothwell, Figg, Ernst & Manbeck
 Street Address: Suite 800, 1425 K St., N.W.
 City: Washington,
 State: D.C. Zip: 20005
 Telephone No.: 202/783-6040
 Facsimile No.: 202/783-6031
 Email Address: bernst@rfem.com
 Attorney Docket No.: 1181-266

6. Total number of applications and patents involved: One7. Total fee (37 CFR 3.41): . . . \$ \$40.00

- ☐ Enclosed
☒ Authorized to be charged to deposit account
☐ None required (government interest not affecting title)

8. Deposit account number: 02-2135

Authorized User Name Barbara G. Ernst

DO NOT USE THIS SPACE

9. Signature.

Barbara G. Ernst
SignatureDec. 15, 2006
DateBarbara G. Ernst

Name of Person Signing

Total number of pages including cover sheet, attachments and documents: 4

CH \$40.00 022135 10221040

EXHIBIT A

In consideration of One Dollar (\$1.00), and other good and valuable consideration, the receipt of which is hereby acknowledged, the undersigned, **Alpharma AS**, a Norwegian corporation with an address at Harbitzalléen 3, N-0275 Oslo, Norway, hereby sells, assigns and transfers to **LYTIX Biopharma** ("Assignee"), a Norwegian corporation under registration with an address at c/o Universitetet i Tromsø, Forskningsavdelingen, 9037 TROMSØ, the entire right, title and interest for the United States and all foreign countries, in and to any and all improvements which are disclosed in the following patents and patent applications:

**Patents and Patent Applications
Included in the Intellectual Property Rights**

1)

Title	Bioactive Peptides (<i>Chemical modifications</i>)
Applicant	ALPHARMA AS; Harbitzalléen 3, N-0275 Oslo, Norway
Patent Number	WO 00/12541
Priority Data	GB 9818938.4. 28 August 1998
International Application	PCT/GB99/02850
National applications	Australia, Canada, Europe (all EPC countries including six extension countries) Japan, Norway, USA

2)

Title	Bioactive Peptide (<i>LFB Derivatives</i>)
Applicant	ALPHARMA AS; Harbitzalléen 3, N-0275 Oslo, Norway
Patent Number	WO 00/12542
Priority Data	GB 9818938.4. 28 August 1998
International application	PCT/GB99/02851 31 August 1999
National applications	Canada, Europe (all EPC countries including six extension countries), USA

PATENT

REEL: 018673 FRAME: 0956

3)	
Title	Methods of Peptide Preparation
Applicant	ALPHARMA AS; Harbitzalléen 3, N-0275 Oslo, Norway
Patent Number	WO 01/19852
Priority Data	GB99/02851 31 August 1999 GB 0005702.6 9 March 2000
International application	PCT/GB00/03378 31 August 2000
National applications	Australia, Canada, Europe (all EPC countries including six extension countries) Japan, Norway, USA

4)	
Title	Antimicrobial Compounds and Formulations
Applicant	ALPHARMA AS; Harbitzalléen 3, N-0275 Oslo, Norway
Patent Number	WO 01/66147
Priority Data	GB 0005703.4 9 March 2000
International Application	PCT/GB01/01035 (9 March 2001)
National Applications	Australia, Canada, Europe (all EPC countries including six extension countries) Japan, Norway, USA

and in and to said application and all divisional, continuing, substitute, renewal, reexamination, reissue, and all other applications for the patents and patent applications listed above which have been or shall be filed in any country, for any improvements; and in and to all original and reissued patents which have been or shall be issued in the United States and all foreign countries on said improvements;

It is agreed that said Assignee may apply for and receive patents for said improvements in its own name, and that, when requested, the undersigned will execute all divisional, continuing, substitute, renewal and reissue, and all other patent applications on any and all said improvements; execute all rightful oaths, assignments,

755
DE

powers of attorney and other papers necessary to secure rights in the patented inventions.



It is further agreed that to the extent practicable, Alpharma AS shall cooperate with the Assignee in any enforcement proceeding, infringement or invalidity proceeding, patent opposition or other legal action affecting the patents and patent applications described above, provided that Assignee shall reimburse Alpharma AS for all expenses incurred as a result of such cooperation, including without limitation, attorney fees, travel expenses and copying charges.

For Alpharma AS



By: Thor Kristiansen
Title: General Manager

For LYTIK Biopharma

By: John Sigurd Svendsen
Øystein Rekdal